Alpheon
Country: Unjoni Ewropea
Lingwa: Taljan
Sors: EMA (European Medicines Agency)
Rapport ta 'Valutazzjoni Pubblika
(PAR)
22-10-2007
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
recombinant human interferon alfa-2a
Disponibbli minn:
BioPartners GmbH
Kodiċi ATC:
L03AB04
INN (Isem Internazzjonali):
interferon alfa-2a
Grupp terapewtiku:
Immunostimolanti,
Żona terapewtika:
Epatite C, cronica
Indikazzjonijiet terapewtiċi:
Adult patients with histologically proven chronic hepatitis C who are positive for hepatitis C virus (HCV) antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation. The efficacy of Interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
L-istatus ta 'awtorizzazzjoni:
rifiutato
